

Evaluation Report for Category L, Subcategory 1.2 Application

Application Number: 2020-0906
Application: Submission subject to the *Protection of Proprietary Interests in Pesticide Data* (PPIP) policy - Equivalency/Data Compensation Assessment
Product: COMPANERO Adjuvant
Registration Number: 34211
Active ingredient (a.i.): Polyoxyalkylated alkyl phosphate ester
PMRA Document Number: 3228712

Purpose of application

The purpose of this application was to register COMPANERO Adjuvant, based on a registered precedent. COMPANERO Adjuvant is a new product to be used as an adjuvant in a tank-mix with labelled postemergence herbicides containing the active ingredient clethodim.

Chemistry assessment

COMPANERO Adjuvant is formulated as a solution containing polyoxyalkylated alkyl phosphate ester at a concentration of 30.0%. This adjuvant has a density of 0.94–0.96 kg/L (20°C) and pH of 2.5–4.0 (1% solution). The required chemistry data for COMPANERO Adjuvant have been provided, reviewed and found to be acceptable.

Health assessments

COMPANERO Adjuvant was considered to be toxicologically equivalent to the precedent product; therefore, no toxicological data were required. COMPANERO Adjuvant is considered to be severely irritating to the eyes and skin, and is not considered to be a dermal sensitizer.

No new residue data were submitted or are required to support the registration of COMPANERO Adjuvant. Previously reviewed residue data for clethodim in the presence of a non-ionic adjuvant were re-assessed in the framework of this application. The use directions on the COMPANERO Adjuvant label, including the formulation type, target crops, adjuvant rate and other use restrictions, are identical to the precedent end-use product. Based on this assessment, residues of clethodim, the active ingredient contained in the tank-mix partners, are not expected to be greater than that for the currently registered uses and will be covered by the established MRLs. Consequently, dietary exposure to residues of clethodim is not expected to increase with the registration of COMPANERO Adjuvant and will not pose health risks of concern to any segment of the population, including infants, children, adults and seniors.

The requested use pattern of COMPANERO Adjuvant is identical to the registered use pattern of the precedent product. Therefore, potential exposure for mixers, loaders, applicators, bystanders and postapplication workers is not expected to exceed the current exposure to the registered products. No health risks of concern are expected for workers and bystanders when label directions, precautions and restrictions are followed.

Environmental assessment

The use pattern for COMPANERO Adjuvant is within the registered use pattern of the active ingredient polyoxyalkylated alkyl phosphate ester. The formulation does not contain any formulants and/or contaminants or impurities that require environmental risk mitigation measures or management. Risk from use of COMPANERO Adjuvant is acceptable from the environmental perspective when used according to label directions.

Value assessment

The availability of COMPANERO Adjuvant will provide farmers with an alternative adjuvant option for use with certain clethodim herbicides. Registration of a generic product may increase product competition in the marketplace, which may in turn reduce purchasing costs of similar products.

The formulation of COMPANERO Adjuvant was compared to the formulation of a precedent product. It was concluded that differences in the formulations would be unlikely to result in any significant impact on product performance, in terms of both efficacy and crop tolerance, when tank mixed with a labelled herbicide product.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information sufficient to support the registration of COMPANERO Adjuvant.

References

PMRA Document Number	Reference
3103030	2020, The Formulation Process of Companero Adjuvant, DACO: 3.2.1, 3.2.2 CBI
3103031	2020, Product Analysis Companero Adjuvant, DACO: 3.4.1 CBI
3103032	2020, The Colour of Companero Adjuvant, DACO: 3.5.1 CBI
3103033	2020, The Physical State of Companero Adjuvant, DACO: 3.5.2 CBI
3103034	2020, Odour Assessment of Companero Adjuvant, DACO: 3.5.3 CBI
3103036	2020, Container Material and Description for Companero Adjuvant, DACO: 3.5.5 CBI
3103037	2020, The Specific Gravity of Companero Adjuvant, DACO: 3.5.6 CBI
3103038	2020, The pH of Companero Adjuvant, DACO: 3.5.7 CBI
3103039	2020, Companero Adjuvant Oxidation/Reduction: Chemical Incompatibility, DACO: 3.5.8 CBI
3103040	2020, The Viscosity of Companero Adjuvant, DACO: 3.5.9 CBI
3103041	2020, Accelerated Storage Stability Study and Corrosion For Companero Adjuvant, DACO: 3.5.10, 3.5.14 CBI
3103042	2020, Flammability of Companero Adjuvant, DACO: 3.5.11 CBI
3103043	2020, Explodability of Companero Adjuvant, DACO: 3.5.12 CBI
3103044	2020, Miscibility of Companero Adjuvant, DACO: 3.5.13 CBI
3103045	2020, Dielectric Breakdown Voltage of Companero Adjuvant, DACO: 3.5.15 CBI
3103046	2020, DACO 3.2.3 Discussion of the Formulation of Impurities of Toxicological Concern DACO 3.4.2 Impurities of Toxicological Concern, DACO: 3.2.3, 3.4.2 CBI
3202058	2020, Accelerated Storage Studies For Companero Adjuvant, DACO: 3.5.10, 3.5.14 CBI
3109071	2020, DACO 5.2 Use Description Scenario (Application and Post-application) for COMPANERO Adjuvant, DACO: 5.2

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2021

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.